Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. The company is headquartered in Palo Alto, California and currently employs 25 full-time employees. The company went IPO on 2014-01-30. The firm is focused on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. Its HDV platform includes lonafarnib, an oral farnesylation inhibitor that targets a critical host process involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV, Combination Therapy for HDV, and Peginterferon Lambda (lambda) for COVID-19. LNF is an orally bioavailable, farnesylation inhibitor that has completed a Phase 3 clinical trial for HDV infection. LNF has demonstrated dose-dependent activity in reducing HDV viral load both as a monotherapy and in combination with ritonavir (RTV) and/or PEG IFN-alfa-2a. Lambda is a type III, well-tolerated interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections.

Industry: Biological Products, (No Diagnostic Substances) Peers: Invivyd Inc Anika Therapeutics Inc Atara Biotherapeutics Inc Kalvista Pharmaceuticals Inc Foghorn Therapeutics Inc Karyopharm Therapeutics Inc Monte Rosa Therapeutics Inc Scholar Rock Holding Corp Vigil Neuroscience, Inc.